About
Fresenius Se & Co. Kgaa (XETRA:FRE) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 9 2026
CMS Grants Fresenius Kabi COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg)
Jan 14 2026
Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement
Dec 18 2025
Fresenius Kabi Introduces First-Ever Rocuronium Bromide Injection Stable at Room Temperature
Dec 4 2025
mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development
Nov 12 2025
Fresenius Kabi’s Adaptive Nomogram used on Aurora Xi Plasmapheresis System Now Operating Nationwide at BioLife Plasma Centers
Financials
Revenue
€22.87 B
Market Cap
€24.55 B
P/E Ratio
16.02
EPS
2.72
Dividend Yield
2.39%
Translate